OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	273
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	172
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods	167
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	124
“Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study	119
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	114
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	96
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination	96
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	92
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	91
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	90
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	86
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	83
The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK	82
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	82
Pre-implementation evaluation for an HPV vaccine provider communication intervention among primary care clinics	79
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	79
Assessing commutability of the first WHO International Standard for antiserum to respiratory syncytial virus	77
Nationwide rollout of HPV vaccination in Nepal: Early key insights	73
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	73
Editorial Board/Aims and Scope	72
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine	72
Editorial Board/Aims and Scope	69
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	67
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	64

Systematic review of pro-equity strategies to improve vaccination among priority populations	63
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	61
The Brucella abortus A19ΔfeuPΔfeuQ double-mutant is highly attenuated and confers protection in BALB/c mice	61
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP)	60
Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink	58
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	57
Herpes zoster mRNA vaccine elicits superior immune responses over licensed vaccines with a favorable safety profile in animal models	57
Advancing the use of vaccine impact modeling for immunization decisions in low- and middle-income countries	56
Effectiveness of the varicella vaccine in the real world, a matched case-control study	56
Safety monitoring of health outcomes following influenza vaccination during the 2023–2024 season among U.S. Commercially-insured individuals aged 6 months through 64 years: Self-controlled case series	55
Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up	53
Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent	53
Racial and ethnic differences among Mpox vaccination recipients by vaccination facility type in New York City—August–December 2022	53
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea	52
A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023	52
Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean	51
Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children	49
Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study	49
Identification of T-cell epitopes of the intracellular parasite Babesia bovis by immunopeptidomic analysis of BoLA-II presented peptides	48
Corrigendum to “Recombinant BCGΔBCG1419c protects outbred mice against M. tuberculosis challenge” [Vaccine 61 (2025) 127347]	48
Corrigendum to “I want to chat with a person”: a qualitative longitudinal cohort study in England exploring drivers of sub-optimal childhood vaccination uptake” [Vaccine 62 (2025) 127462]	48
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	47